Home / Ophthalmology
Neovascular eye disease
An injectable hydrogel, proposed to replace monthly injections.
Ophthalmology
SAPHTx: an injectable hydrogel for the back of the eye
The proposed solution is a cost-effective, long lasting, and injectable hydrogel called SAPHTx. This hydrogel is composed exclusively of naturally occurring amino acids engineered to include an anti-angiogenic peptide.
The intent is a treatment that lasts, delivered by injection, so that patients are not returning every month for an anti-VEGF dose.
The problem
Why another injection
Two leading causes of blindness
Age-related macular degeneration (AMD) and diabetic retinopathy (DR) are leading causes of blindness worldwide, and the burden falls on older, diabetic and under-represented populations.
Abnormal vessel growth
Proliferation of maladaptive blood vessels on the retina characterises these posterior-segment neovascular diseases.
Monthly injections
The standard of care is monthly intraocular injections of VEGF inhibitors — costly, uncomfortable, and carrying a risk of endophthalmitis.
Lasers are not the answer
Laser ablation is not preferred: scarring, disease recurrence, invasiveness and higher inpatient costs.
Market
A market measured in billions
The total market for AMD is estimated to be greater than $5 billion and is expected to reach $11.5 billion by 2026, with an 8.9% compound annual growth rate. Key players include Lucentis, Eylea, Avastin and Visudyne, with others in clinical trials.
Figures as published in the 2019 abstract, attributed to that source.
Where this programme stands
It was presented as a proposed solution in a 2019 Biomaterials Society abstract from the New Jersey Institute of Technology. No clinical trial, regulatory filing or approval is claimed for it anywhere on this site.